U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07861412) titled 'A Prospective Interventional Study of Intranasal Zavegepant for the Acute Treatment of Migraine' on Sept. 11.
Brief Summary: Primary Objective:
To evaluate the effectiveness of zavegepant in real-world settings for the acute treatment of migraine. Effectiveness will be evaluated based on the treatment of the first acute migraine attack with zavegepant, in order to capture clinically meaningful treatment response under real-world conditions while minimizing patient burden and missing data. Clinically meaningful treatment response is defined as: An improvement in a patient's condition that is large enough to be perceived as beneficial...